profit from every $100 of sales.
$0$100
Cumberland Pharmaceuticals
$5.88-11.31% today
+462.7% in 1 year
1-year low $0.951-year high $6.63
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cumberland Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $42.0 million in 2022 to $44.5 million in 2025, with -$2.84 million of profit last year.
SalesProfit
Cumberland Pharmaceuticals handed back 6% of the cash it generated last year.
Buybacks $263,478
Free cash flow 2025$5M
Bought back its own shares$263,478
Paid as dividends–
Cash vs. debt$11M vs. $10M
Cumberland Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cumberland Pharmaceuticals | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Cumberland Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 42 | 40 | 38 | 45 | |
| 33 | 33 | 31 | 38 | |
| -6 | -10 | -6 | -3 | |
| 0 | 2 | 0 | 3 | |
| -6 | -6 | -6 | -3 | |
| -0.38 | -0.44 | -0.46 | -0.19 | |
| 78.3% | 84.7% | 82.6% | 85.0% | |
| -13.6% | -24.2% | -17.0% | -6.3% | |
| -13.3% | -15.9% | -17.1% | -6.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 93 | 82 | 76 | 77 |
| Cash | 20 | 18 | 18 | 11 |
| Total debt | 21 | 18 | 21 | 10 |
| Total liabilities | 57 | 53 | 53 | 52 |
| 36 | 30 | 23 | 25 | |
| 15 | 14 | 14 | 15 | |
| -6.9% | -9.2% | -10.7% | -5.2% | |
| -15.4% | -21.2% | -28.4% | -11.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 8 | 6 | -1 | 5 | |
| 2 | 0 | 0 | 0 | |
| 6 | 6 | -1 | 5 | |
| Dividends paid | – | – | – | – |
| 1 | 1 | 1 | 0 | |
| 0 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 3.8×
- 2.0×
- 18.6×
- 29.3×
- 5.4%
- -3.2%
- 0.0%
Profitability
- 85.0%
- -6.3%
- -6.4%
- -4.5%
- -19.5%
- -10.4%
- -28.7%
- -10.2%
- -19.8%
- 13.7%
Growth
- +2.0%
- –
- +710.5%
- –
- +0.1%
Financial health
- 0.5×
- 0.47
- 14.2%
- -17.3×
- 0.95
- 0.79
- 0.59
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 18%of 963
Bottom 15%of 894
Bottom 21%of 908
Top 21%of 991
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.13 | -0.13 | +0.0% |
| Mar 3, 2026 | -0.01 | -0.13 | +92.3% |
| Nov 4, 2025 | -0.06 | – | – |
| Aug 5, 2025 | 0.02 | – | – |
| May 6, 2025 | 0.16 | – | – |
| Mar 4, 2025 | -0.02 | – | – |
| Nov 7, 2024 | -0.02 | – | – |
| Aug 6, 2024 | 0.01 | – | – |
News
Cumberland outlines plan to fund operations for over 5 years as it prepares rolling NDA submission for ifetroban in DMDSeeking Alpha · Nov 10, 2026Cumberland announces ifetroban NDA filing plan after shares plummetSeeking Alpha · Oct 26, 2026Couche-Tard makes bid for Cumberland Farms: reportSeeking Alpha · Oct 24, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
23No pass
Philip Fisher
37No pass
Peter Lynch
29No pass
Joel Greenblatt
2No pass
Charlie Munger
31No pass
Terry Smith
24No pass
Questions about Cumberland Pharmaceuticals
Is Cumberland Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cumberland Pharmaceuticals AI analysis
What does Cumberland Pharmaceuticals do?
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. It is in Drug Manufacturers - Specialty & Generic.
Does Cumberland Pharmaceuticals pay a dividend?
No. Cumberland Pharmaceuticals does not pay a dividend at the moment; in 2025 it returned $263,478 to shareholders by buying back its own shares.
Is Cumberland Pharmaceuticals stock halal?
Yes. Cumberland Pharmaceuticals passes our halal screen: its business is permitted and its debt is 12% of its market value, under the 30% limit. How we check
How has Cumberland Pharmaceuticals stock done over the past year?
Up 462.7% over the past twelve months, to $5.88. It traded between $0.95 and $6.63 and is 11.3% below its high.
Who are Cumberland Pharmaceuticals's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Cumberland Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.